Clinical Trial Update: Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion [Phase 4]

View source ↗

Summary

Phase 4 trial comparing Ozurdex to Lucentis for safety and efficacy in retinal vein occlusion with macular edema has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Edema
• Retinal Vein Occlusion

Drugs mentioned

• Lucentis (ranibizumab)
• Ozurdex (dexamethasone intravitreal implant)

Snippet

Sponsor: Allergan | Conditions: Retinal Vein Occlusion, Macular Edema | Phase 4 | Status: COMPLETED | Results posted: 2016-02-15